# Shennon Biotechnologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shennon-biotechnologies

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.shennonbio.com
- Total disclosed funding: $7.3M
- Latest round: Seed (Dec 21, 2022)
- Investors on record: 3

## About

Based in California, US, and founded in 2021, Shennon Biotechnologies operates as a biotechnology research company that develops treatments for solid tumors and later autoimmune diseases. The company was founded by its CEO Li Sun. In September 2026, Shennon Biotechnologies Inc. raised USD 12 million in venture funding from Atypical Ventures, Future Ventures, NextGen Venture Partners, Samos Investments,  Saras Capital, AV8 Ventures, DCVC, and Foundation Capital. The firm uses an ultra-high throughput single-cell platform which helps the company to profile immune cells on single cell level and pull-out targets. This platform helps the firm to create immunotherapies. The firm plans to use the September 2026 fundingt o advance its cancer treatment programs and support development of its T-cell engager platform for clinical studies.

## Funding rounds

- Seed, Dec 21, 2022, $7.3M — Foundation Capital, DCVC, AV8 Ventures

## Investors

- Foundation Capital (https://capitalatlas.ai/funds/foundation-capital) — Seed
- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed
- AV8 Ventures (https://capitalatlas.ai/funds/av8-ventures) — Seed